Eisai Differentially Prices Aricept In Certain Asian Markets

Eisai is to cut the price of its Alzheimer's disease therapeutic Aricept (donepezil) in six Asian countries. BMI notes that this tactic is in accordance with one of our short-term core views: drugmakers will increasingly use differential pricing in emerging markets.

To read the full article, please choose one of the following options: